Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Executive Summary
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
You may also be interested in...
Genta Postscript: Defunct Company’s Former President Charged With Insider Trading
Loretta Itri told a longtime friend of the negative results of a Phase III study of Genasense in advanced melanoma before the news was public.
Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows
By targeting a population with an unmet medical need that would qualify for review under FDA's accelerated approval regulations, GlaxoSmithKline and Genmab transcended a "suboptimal" development program and "uncertainty" regarding the magnitude of treatment effect to bring their anti-CD20 monoclonal antibody Arzerra (ofatumumab) to market, FDA review documents show
Genta Poised To Restart Tesetaxel Studies
FDA lifts clinical hold on Phase II oral taxane now headed back to the clinic in the second half.